4 Results for "

Polatuzumab

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "Polatuzumab" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P99042
CAS No.: 2279068-37-8
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132253
CAS No.: 1313206-42-6
Purity:  98.83%
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-132253A
CAS No.: 1313206-42-6
Purity:  98.36%
Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
loading...
    loading...
Cat. No.: HY-184561
CAS No.: 3128805-51-3
Research Areas:  

Cancer

L05-EXd is a toxin-linker conjugate, in which the toxin component is Exatecan (HY-13631). L05-EXd can be conjugated with Polatuzumab (HY-P99042) to form the ADC molecule Polatuzumab-L05-EXd. L05-EXd is applicable to research related to small cell lung cancer and non-small cell lung cancer .
loading...
    loading...